AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aquestive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
Aquestive Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacture and supply revenue | $11.91M | $8.79M | $11.98M | $11.47M | $9.58M | $7.19M | $10.66M | $10.67M | $8.12M | $10.52M | $11.00M | $11.41M | 86.2% | +24.3% |
| License and royalty revenue (a) | $1.33M | $5.40M | $852.00K | $1.04M | $839.00K | $790.00K | $831.00K | $2.16M | $11.22M | $1.13M | $1.87M | $1.10M | 9.6% | +58.0% |
| Royalty | $976.00K | $0 | $16.00K | $8.00K | $914.00K | $0 | $1.94M | – | – | -$12.00K | $1.98M | $0 | 7.1% | +6.8% |
| Co-development and research fees | $582.00K | $258.00K | $181.00K | $302.00K | $378.00K | $418.00K | $274.00K | $492.00K | $756.00K | $403.00K | $335.00K | $490.00K | 4.2% | +54.0% |
| Proprietary product revenue, net | $0 | $0 | – | – | -$797.00K | $319.00K | – | – | – | – | – | – | 0.0% | -100.0% |
| Proprietary product sales, net | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Proprietary product revenue, net | – | – | – | $0 | -$797.00K | $319.00K | – | $217.00K | $0 | $0 | – | $0 | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $10.99M | $13.25M | $9.39M | $10.12M | $4.89M | $5.20M | $9.33M | $10.53M | $9.64M | $10.43M | $11.73M | $9.89M | 79.5% | +124.7% |
| Ex-United States | $2.83M | $1.20M | $3.63M | $2.68M | $5.11M | $3.52M | $2.54M | $3.01M | $10.46M | $1.63M | $1.47M | $3.11M | 20.5% | -44.7% |
From the segment and revenue-disaggregation notes of Aquestive Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.